Segments - Acne Drugs Market by Type (Comedonal, Inflammatory, Cystic, and Postsurgical/wound), Therapeutic Class (Retinoid, Antibiotic, Hormonal Agent, Combination, and Others), and Mode of Administration (Topical, Oral, and Injectable), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 - 2031
The global acne drugs market size was valued at USD 10.38 Billion in 2022 and is projected to reach USD 16.40 Billion by 2031, expanding at a CAGR of 5.1% during the forecast period 2023 - 2031. The growth of the market is attributed to the introduction of biologics, unhealthy lifestyle, and increasing disease prevalence.
Acne is a chronic, inflammatory skin disorder that produces pimples and spots on the face, shoulders, back, neck, chest, and upper arms, among other areas. Acne develops when oil, dead skin, or germs clog the pores of the skin. Each skin pore is a follicle's opening. A hair and a sebaceous (oil) gland make up the follicle. Sebum (oil) is produced by the oil gland and travels up the hair shaft, out of the pore, and onto the skin. Sebum lubricates and softens the skin.
Acne can be caused by one or more issues with the lubrication process. It can happen when your follicles generate too much oil, dead skin cells pile up in your pores, or bacteria build up in your pores. All of these issues lead to the formation of pimples. When bacteria develop in a blocked pore and the oil cannot leave, a pimple form.
Acne has a lot of misconceptions regarding what causes it. Many individuals believe that certain foods, such as chocolate and French fries, cause acne. While there is no scientific evidence to back up these assertions, there are certain risk factors for acne. Hormonal changes brought on by puberty or pregnancy, certain drugs such as birth control pills or corticosteroids, a diet heavy in refined sugars or carbs such as bread and chips and having acne-prone parents are all risk factors.
Acne is more common in young people throughout puberty. The body goes through hormonal changes at this period. These changes may increase oil production, putting you at risk for acne. When you reach maturity, hormonal acne associated with puberty typically fades or improves. It is crucial to figure out the type of acne individual have before starting its treatment. Acne can be either non-inflammatory or inflammatory in nature. Blackheads, whiteheads, papules, pustules, nodules, and cysts are all forms of acne that fall into these two categories.
If self-care is not working, there are a few over-the-counter acne medicines to try. The majority of these medicines contain chemicals that can aid in the killing of germs or the reduction of oil on the skin. Benzoyl peroxide, which is found in many acne treatments and gels, is one of them. It is used to dry up existing pimples and prevent new ones from forming. Acne-causing bacteria are also killed by benzoyl peroxide. Sulfur is a natural component that may be found in certain lotions, cleansers, and masks and has a unique odor.
Resorcinol is a less commonly used chemical for exfoliating dead skin cells. Soaps and acne wash frequently include salicylic acid. It aids in the prevention of clogged pores. Pimples are a common skin condition that can be frustrating to cure. Applying essential oils, green tea, and aloe vera to the skin appears to be the quickest solution to get rid of pimples, whereas supplements, according to some limited study, may require longer-term use.
The report on the global acne drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Acne Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Type (Comedonal, Inflammatory, Cystic, and Postsurgical/wound), Therapeutic Class (Retinoid, Antibiotic, Hormonal Agent, Combination, and Others), and Mode of Administration (Topical, Oral, and Injectable) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Alma Lasers Ltd.; Lumenis Ltd.; Cutera, Inc.; Stiefel Laboratories Inc.; GlaxoSmithKline Plc.; Galderma S.A.; Valeant Pharmaceutical International, Inc.; Verilux, Inc.; Johnson and Johnson; Syneron Medical Ltd; and Allergan plc. |
Based on type, the acne drugs market is segmented into comedonal, inflammatory, cystic, and postsurgical/wound. The inflammatory segment is expected to account for a key share of the market during the forecast period owing to its increasing demand worldwide. Symptoms of inflammatory acne include redness, swelling, and severely clogged pores filled with dirt, germs, and dead skin cells. Bacterial infection might exacerbate the problem.
Cystic acne is the most severe type of acne and affects a smaller number of people. The majority of over-the-counter medications are ineffective in treating cystic acne. After a bacterial infection at the wound/surgery site, post-surgical/wound acne develops.
Based on therapeutic class, the acne drugs market is segmented into retinoid, antibiotic, hormonal agent, combination, and others. The retinoids and antibiotics segment are expected to constitute a key share of the market during the forecast period owing to their first-line action and impending approval of pipeline products.
On the other hand, the combination segment is anticipated to expand at a rapid pace during the forecast period owing to its higher efficacy, improved results, reduced resistance, and convenient usage. Hormonal agents are usually utilized in the most serious situations. Oral contraception is a common type of hormonal acne therapy.
Women who, in addition to suffering from acne, are interested in contraceptive advantages typically prefer this technique. Hormonal treatment, on the other hand, is used in conjunction with benzoyl peroxide, azelaic acid, antibiotics, and retinoids. Sulfur, hydroxy acids, BPO, salicylic acid, and azelaic acid are some of the other treatments employed.
Based on mode of administration, the acne drugs market is segmented into topical, oral, and injectable. The topical segment is expected to represent a key share of the market during the forecast period as for mild-to-moderate acne and maintenance therapy, retinoids, antibiotics, BPO, salicylic acid, and azelaic acid are used topically. When topical treatments fail to elicit a response, oral medicines are indicated as systemic therapy.
On the other hand, the injectable segment is anticipated to expand at a rapid pace during the forecast period owing to introduction of several biologics. Cortisone injections may be required to treat highly inflammatory or cystic acne.
On the basis of regions, the acne drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to lifestyle changes, rising disease incidence, and easy availability of products.
On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increased number of product launches, high demand for effective acne treatment, growing healthcare expenditure, and rising awareness regarding the treatment options.
The global acne drugs market has been segmented on the basis of
Key players competing in the acne drugs market are Alma Lasers Ltd.; Lumenis Ltd.; Cutera, Inc.; Stiefel Laboratories Inc.; GlaxoSmithKline Plc.; Galderma S.A.; Valeant Pharmaceutical International, Inc.; Verilux, Inc.; Johnson and Johnson; Syneron Medical Ltd; and Allergan plc.
Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. For example, in April 2021, Galderma announced the launch of Aklief, an acne treatment medication, in South Korea. This medication targets the retinoid receptor gamma in the retinoic acid receptor (RAR) in the skin, making acne therapy more efficient and effective. This strategic decision will help the corporation grow its operations in South Korea.
Another example would be, in January 2021, GlaxoSmithKline announced a research collaboration with Eligo Bioscience. Eligobiotics' acne vulgaris therapy uses cutting-edge CRISPR-based therapeutic technology. This strategic partnership is anticipated to speed up research and development operations, giving the firm a competitive advantage.